The new network will facilitate the development of new drugs and other therapies for the entire paediatric population in Europe. Credit: courtesy of the University of Liverpool.

Paediatric specialists in Europe have launched a consortium to work on the development of new drugs and additional therapies for children.

The Collaborative Network for European Clinical Trials for Children, otherwise known as conect4children (c4c), will be comprised of researchers from 33 academic institutions and ten industry partners from 20 European nations, as well as more than 50 third party groups and approximately 500 affiliated collaborators.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The consortium aims to leverage existing expertise and patient access in order to improve competitiveness of Europe for making paediatric drugs.

In addition, the partners intend to create processes that can be applied to disease natural history and new treatment studies, registries, and comparisons of existing therapies.

Over the next six years, the c4c network will devise a pan-European framework to design and implement multinational clinical trials for children across Europe, while building connections with regulators.

“This network will have a significant impact on how we develop much-needed innovative and improved medicines.”

Their efforts will also include new trial designs and quantitative methods to develop medicines for rare paediatric conditions and high medical need areas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The University of Liverpool Institute of Translational Medicine clinical neonatologist Dr Mark Turner said: “This network will have a significant impact on how we develop much-needed innovative and improved medicines for babies, children and young people.

“A number of collaborations built up over the past decade will contribute to this pan-European research network.”

Turner will lead the development and implementation of the network, while the c4c hub in the UK will be headed by the Liverpool University’s Child Health professor Michael Beresford.

The c4c project is being funded by Europe’s largest public private partnership Innovative Medicines Initiative 2 Joint Undertaking, which is financially supported by the European Union’s Horizon 2020 research and innovation programme and the region’s pharmaceutical industry.